NO343189B1 - Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat - Google Patents

Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat

Info

Publication number
NO343189B1
NO343189B1 NO20081327A NO20081327A NO343189B1 NO 343189 B1 NO343189 B1 NO 343189B1 NO 20081327 A NO20081327 A NO 20081327A NO 20081327 A NO20081327 A NO 20081327A NO 343189 B1 NO343189 B1 NO 343189B1
Authority
NO
Norway
Prior art keywords
alkyl
cycloalkyl
group
heteroaryl
aryl
Prior art date
Application number
NO20081327A
Other languages
English (en)
Other versions
NO20081327L (no
Inventor
George Hynd
Harry Finch
Michael Colin Cramp
Rosa Arienzo
Peter Crackett
Yann Griffon
Trevor Keith Harrison
John Gary Montana
Nicholas Charles Ray
Original Assignee
Pulmagen Therapeutics Asthma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0519969.0A external-priority patent/GB0519969D0/en
Priority claimed from GB0610551A external-priority patent/GB0610551D0/en
Application filed by Pulmagen Therapeutics Asthma Ltd filed Critical Pulmagen Therapeutics Asthma Ltd
Publication of NO20081327L publication Critical patent/NO20081327L/no
Publication of NO343189B1 publication Critical patent/NO343189B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)

Abstract

Forbindelser med formel [1] er CRTH2 antagonister, anvendelige ved behandling av lidelser som har en inflammatorisk komponent: [1] hvor: R1, R2, R3, R4 og R5 er uavhengig hydrogen, C1-C6alkyl, C1-C6fluoralkyl, cyklopropyl, halogen, -S(O)nR6, -SO2NR7R8, -NR7R8, -NR7C(O)R6, -CO2R7, -C(O)NR7R8, -C(O)R6, -NO2, -CN eller en gruppe -OR9; hvor hver R6 er uavhengig C1-C6alkyl, C1-C6fluoralkyl, cykloalkyl, aryl eller heteroaryl; R7, R8 er uavhengig C1-C6alkyl, C1-C6fluoralkyl, cykloalkyl, cykloalkyl-(C1-C6alkyl)-, aryl, heteroaryl eller hydrogen; R9 er hydrogen, C1-C6alkyl, C1-C6fluoralkyl, cykloalkyl, cylcoalkyl-(C1-C6alkyl)- eller en gruppe -SO2R6; A er -CHR10-, -C(O)-, -S(O)n-, -O- eller -NR10- hvor n er et helt tall fra 0-2 og R10 er hydrogen, C1-C3alkyl eller C1-C6fluoralkylgruppe; B er en direkte binding eller en divalent rest valgt fra -CH2-, -CH2CH2-, -CHR11-, -CR11R12-, -CH2CHR11-, -CH2CR11R12-, -CHR11CHR12- og divalente rester med formel -(CR11R12)p-Z- hvor Z er bundet til ringen som bærer R1, R2 og R3; hvor R11 er C1-C3alkyl, cyklopropyl, C1-C6fluoralkyl; R12 er metyl eller fluormetyl; p er uavhengig 1 eller 2; og Z er -O-, -NH- eller -S(O)n-, hvor n er et helt tall fra 0-2; X er en karboksylsyre, tetrazol, 3-hydroksyisoksazol, hydroksamsyre, fosfinat, fosfonat, fosfonamid eller sulfonsyregruppe eller en gruppe med formel C(=O)NHSO2R6 eller SO2NHC(=O)R6; og Y er aryl, heteroaryl, aryl-kondensert-heterocykloalkyl, heteroaryl-kondensert-cykloalkyl, heteroaryl-kondensert-heterocykloalkyl eller aryl-kondensert-cykloalkylgruppe. 1
NO20081327A 2005-09-30 2008-03-13 Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat NO343189B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0519969.0A GB0519969D0 (en) 2005-09-30 2005-09-30 Quinoline compounds
GB0610551A GB0610551D0 (en) 2006-05-26 2006-05-26 Quinoline compounds
PCT/GB2006/003644 WO2007036743A2 (en) 2005-09-30 2006-09-29 Quinolines and their therapeutic use

Publications (2)

Publication Number Publication Date
NO20081327L NO20081327L (no) 2008-06-19
NO343189B1 true NO343189B1 (no) 2018-11-26

Family

ID=37579213

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081327A NO343189B1 (no) 2005-09-30 2008-03-13 Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat

Country Status (17)

Country Link
US (1) US7858640B2 (no)
EP (1) EP1928457B1 (no)
JP (1) JP4990285B2 (no)
AU (1) AU2006296397B2 (no)
BR (1) BRPI0616452B8 (no)
CA (1) CA2622000C (no)
DK (1) DK1928457T3 (no)
EA (1) EA015358B1 (no)
ES (1) ES2399061T3 (no)
HK (1) HK1124784A1 (no)
IL (1) IL190055A (no)
NO (1) NO343189B1 (no)
NZ (1) NZ566537A (no)
PL (1) PL1928457T3 (no)
PT (1) PT1928457E (no)
SI (1) SI1928457T1 (no)
WO (1) WO2007036743A2 (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200802417A1 (ru) * 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
JP5280357B2 (ja) 2006-07-07 2013-09-04 スティーブン・ピー・ガベック Ｐｄｅ４の二環式ヘテロアリール阻害剤
US8138205B2 (en) 2006-07-07 2012-03-20 Kalypsys, Inc. Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
WO2008119917A1 (en) * 2007-03-29 2008-10-09 Argenta Discovery Limited Quinoline derivatives as crth2 receptor ligands
DK2139881T3 (da) * 2007-04-04 2012-01-30 Pulmagen Therapeutics Asthma Ltd Quinoliner og deres terapeutiske anvendelse
GB0722055D0 (en) * 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
CA2707785C (en) 2007-12-14 2015-11-03 Pulmagen Therapeutics (Asthma) Limited Indoles and their therapeutic use
GB0818365D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinoline compounds
GB0818366D0 (en) * 2008-10-07 2008-11-12 Argenta Discovery Ltd Quinolin-2-one-compounds
US8188090B2 (en) * 2008-11-17 2012-05-29 Hoffman-La Roche Inc. Naphthylacetic acids
KR101920090B1 (ko) 2010-07-05 2018-11-19 이도르시아 파마슈티컬스 리미티드 1-페닐-치환된 헤테로시클릴 유도체 및 프로스타글란딘 ｄ２ 수용체 조절자로서 이의 용도
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EA026456B1 (ru) 2011-12-16 2017-04-28 Атопикс Терапьютикс Лимитед Фармацевтическая композиция на основе антагониста crth2 и ингибитора протонного насоса для лечения эозинофильного эзофагита
CA2858328A1 (en) 2011-12-21 2013-06-27 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
CA3228632A1 (en) 2015-12-24 2017-06-29 Kyowa Kirin Co., Ltd. .alpha.,.beta.-unsaturated amide compound
KR20190018643A (ko) * 2016-05-16 2019-02-25 풀마젠 테라퓨틱스 (애즈마) 리미티드 퀴놀린 유도체의 결정
KR20200019979A (ko) 2017-06-23 2020-02-25 쿄와 기린 가부시키가이샤 α, β 불포화 아미드 화합물
WO2020172380A1 (en) 2019-02-22 2020-08-27 Gb001, Inc. Treatment of asthma patients having high baseline feno levels
US20200354374A1 (en) * 2019-05-06 2020-11-12 Inspira, LLC Chemical Entities, Pharmaceutical Formulations, and Methods for Treating Fibrosis
WO2020227570A1 (en) 2019-05-08 2020-11-12 Gb001, Inc. Methods of treating chronic rhinosinusitis with pexopiprant

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101330A2 (en) * 1982-06-21 1984-02-22 Nippon Shinyaku Company, Limited 2-Quinolone derivatives
WO2003066046A1 (en) * 2002-02-05 2003-08-14 Astrazeneca Ab Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW297025B (no) * 1992-02-14 1997-02-01 Squibb & Sons Inc
MXPA03007765A (es) * 2001-03-01 2003-12-08 Shionogi & Co Compuestos heteroarilo que contienen nitrogeno, que tienen actividad inhibitoria contra virus de inmunodeficiencia humana integrasa.
US7358249B2 (en) * 2002-08-13 2008-04-15 Shionogi & Co., Ltd. Heterocyclic compounds having inhibitory activity against HIV integrase
EP1556047A4 (en) * 2002-10-04 2009-09-30 Millennium Pharm Inc ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) * 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
EP1758579A1 (en) * 2004-05-29 2007-03-07 7TM Pharma A/S Crth2 receptor ligands for medicinal uses
UY29223A1 (es) * 2004-11-23 2006-06-30 Astrazeneca Ab Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0101330A2 (en) * 1982-06-21 1984-02-22 Nippon Shinyaku Company, Limited 2-Quinolone derivatives
WO2003066046A1 (en) * 2002-02-05 2003-08-14 Astrazeneca Ab Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists

Also Published As

Publication number Publication date
IL190055A0 (en) 2008-08-07
HK1124784A1 (en) 2009-07-24
ES2399061T3 (es) 2013-03-25
WO2007036743A2 (en) 2007-04-05
IL190055A (en) 2015-07-30
NO20081327L (no) 2008-06-19
SI1928457T1 (sl) 2013-06-28
PT1928457E (pt) 2013-02-19
PL1928457T3 (pl) 2013-04-30
US7858640B2 (en) 2010-12-28
JP2009510045A (ja) 2009-03-12
CA2622000C (en) 2014-01-21
DK1928457T3 (da) 2013-02-04
WO2007036743A3 (en) 2007-09-20
EA200800640A1 (ru) 2008-10-30
BRPI0616452B1 (pt) 2020-10-13
EP1928457B1 (en) 2012-12-12
CA2622000A1 (en) 2007-04-05
NZ566537A (en) 2010-10-29
BRPI0616452B8 (pt) 2021-05-25
EP1928457A2 (en) 2008-06-11
EA015358B1 (ru) 2011-06-30
AU2006296397B2 (en) 2011-12-15
BRPI0616452A2 (pt) 2011-06-21
AU2006296397A1 (en) 2007-04-05
JP4990285B2 (ja) 2012-08-01
US20090156600A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
NO343189B1 (no) Kinoliner og terapeutisk anvendelse derav, samt farmasøytisk preparat
RU2403253C2 (ru) Пуриновые производные для применения в качестве агонистов аденозинового рецептора а-2а
AR077505A1 (es) Compuestos de piridina y sus usos
NO20091599L (no) Kjemiske forbindelser
ATE448193T1 (de) ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
JP2011527334A5 (no)
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
PE20080769A1 (es) Derivados de biaril-sulfonamida
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
PE20081475A1 (es) Arilamidas sustituidas por tiazol u oxazol
EA200900606A1 (ru) Новые сульфониламидные производные в качестве антагонистов брадикининовых рецепторов
PH12015502114B1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
EA200971115A1 (ru) Новые ингибиторы обратной транскриптазы вич
MY145603A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-a]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
NO20085031L (no) Benzimidazolmodulatorer av VR1
GB0512944D0 (en) Indolizine compounds
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
AR075583A1 (es) Derivados de isoxazol/o-piridina con eslabon etilo o etenilo
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
JP2011526917A5 (no)
ATE473221T1 (de) 1-(1-benzylpiperidin-4-yl)benzimidazol-5- carbonsäurederivate zur behandlung von diabetes mellitus
NO20076145L (no) Ureadeviater, fremgangsmater for deres fremstilling og anvendelse derav
PE20091426A1 (es) Compuestos de piridina
AR077534A1 (es) Derivados de isoxazol, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con el receptor gaba aalfa5

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GB001, US

MM1K Lapsed by not paying the annual fees